Utepreva LLC has received FDA clearance for its single-use endometrial sampler, which employs three sampling mechanisms to improve tissue yield for cytologic and molecular analysis in early endometrial cancer detection.
A study identified microRNA patterns in blood plasma that could support noninvasive diagnosis and monitoring of the most aggressive form of brain cancer.
Presentations at AACR 2026 will showcase fragmentomics-based technology for detecting therapeutic markers and providing prognostic insight.
Biodesix will present seven abstracts—including two oral sessions—at AACR 2026, highlighting advances in automated myeloid testing, liquid biopsy, and NGS-based cancer monitoring platforms.
Read More
Data from nearly 1,900 SEER-linked patients show the test identifies meaningful survival differences within the same AJCC stage.
Read More
The updated urine test utilizes machine learning and patient ethnicity to provide individualized risk scores for aggressive disease.
Read More
A new survey-based study finds that more than half of physically Disabled women would prefer at-home human papillomavirus testing over traditional clinic-based cervical screening.
Read More
A new study validates a machine-learning platform that detects prostate cancer through biochemical patterns in urine samples.
Read More
Caris Life Sciences has launched Caris ChromoSeq, a whole genome and transcriptome sequencing assay for myeloid malignancies, designed to consolidate multiple tests into a single workflow with a seven-day turnaround.
Read More
Irish researchers have secured €670,000 to clinically validate a blood-based colorectal cancer screening test using inflammatory biomarkers, aiming for launch by 2027 through a new spin-out company.
Read More
The BiliSeq molecular test detected bile duct cancer in 82% of cases—compared to 44% with standard pathology—according to a six-year, multi-institutional study.
Read More
Using causal artificial intelligence and digital pathology, the test moves beyond population-level averages to predict patient-specific chemotherapy outcomes.
Read More
The collaboration pairs AI pathology algorithms with global laboratory infrastructure to help biopharma teams speed up evidence generation and diagnostic launch timelines.
Read More
A Mayo Clinic study of 674 trauma patients found elevated circulating nucleosome levels in those who developed venous thromboembolism, suggesting a potential new biomarker for early VTE risk identification.
Read More
Inherited variants in the DPYD gene can increase the risk of life-threatening toxicity from fluoropyrimidine-based chemotherapies, yet screening remains inconsistent across care settings.
Read More
A retrospective study in Lymphatics reports that CSF liquid biopsy testing delivered clinical impact in 82% of CNS lymphoma cases, resolving diagnoses and informing treatment when standard methods were inconclusive.
Read More
A novel enrichment method produces virtually pure circulating tumor DNA from blood samples, showing strong sensitivity and specificity across colorectal and lung cancer patients.
Read More
Preoperative blood testing using H3K27Me3-nucleosome levels may help clinicians identify which non-small cell lung cancer patients need closer follow-up or additional treatment.
Read More